Panloc
Generic Name: Pantoprazole
Therapeutic Class: ANTI-ULCERANTS
Presentation
Panloc 20 Tablet Each box contains 5x10's in Alu-Alu blister strips.
Panloc 40 Tablet Each box contains 3x10's in Alu-Alu blister strips.
Description
Panloc (Pantoprazole) leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the H+/K+ATPase results in duration of antisecretory effect that persists longer than 24 hours. Panloc (Pantoprazole) is quantitatively absorbed and bioavailability does not change upon multiple dosing. Panloc (Pantoprazole) is extensively metabolized in the liver. Almost 80% of an oral dose is excreted as metabolites in urine; the remainder is found in feces and originates from biliary secretion.
Indication
Panloc (Pantoprazole) is indicated where suppression of acid secretion is of therapeutic benefit. Panloc (Pantoprazole) is registered for the following indications:
1. Peptic ulcer diseases (PUD)
2. Gastro esophageal reflux diseases (GERD)
3. Treatment of ulcer resistant to H2 receptor antagonists (H2RAs)
4. Non-steroidal anti-inflammatory drugs (NSAIDs) induced ulcers
5. Gastrointestinal (GI) bleeding from stress or acid peptic diseases
6. Eradication of Helicobacter pylori (in combination with antibiotics)
7. Zollinger-Ellison syndrome
8. Prophylaxis for acid aspiration syndrome during induction of anaesthesia
Dosage & Administration
The usual recommended adult oral dose is 40 mg given once daily, before breakfast. The duration of therapy is ranging from 2-8 weeks. Duodenal Ulcers: 40 mg tablet, once daily for 2 to 4 weeks. Duodenal ulcer generally heals within 2 weeks. Gastric ulcers: 40 mg tablet, once daily for 4 to 8 weeks. Gastric ulcer generally heals within 4 weeks. Reflux esophagitis: 40 mg tablet, once daily for 4 to 8 weeks. Reflux esophagitis generally heals within 4 weeks of treatment. In resistant ulcers: 40 mg tablet, once daily for 8 weeks. Ulcers induced by NSAIDs: 40 mg tablet once daily, in patients receiving continuous treatment with NSAIDs. GI bleeding from stress or acid peptic diseases: Usual adult oral dosage, if required the dosage may be increased. Eradication of Helicobacter pylori: Triple therapy of 40 mg twice daily in combination with appropriate antibiotic for one week achieved eradication rates of 90 to100%. Zollinger-Ellison syndrome: 4 tablets of 40 mg Pantoprazole per day. Once control of acid secretion has been achieved, the dose should be gradually reduced to the lowest effective dose that maintains acid control. Prophylaxis for acid aspiration syndrome during induction of anaesthesia: 1 or 2 Pantoprazole 40 mg tablet should be given the evening before surgery and repeated again the morning of surgery. Maintenance therapy: Maintenance treatment should involve the lowest dose of the drug. Both 20 and 40 mg doses of Pantoprazole are safe and effective in maintaining patients with healed reflux esophagitis and PUD in remission.
Side Effect
Potentially life-threatening effects: None has been reported with respect to Pantoprazole. Severe or irreversible adverse effects: No serious adverse reactions have been described to date. Symptomatic adverse effects: Headache and diarrhoea are the two commonest reported adverse events. It doesn't influence renal, cardiovascular, respiratory, endocrine, cognitive or motor functions and no consistent change have been found in any biochemical or haematological parameters. Peripheral edema has occasionally been reported in female patients. Other side effects may include abdominal pain, dizziness, nausea, epigastric discomfort, flatulence, skin rash, pruritus etc.
Precautions
Before using this medication, tell doctor medical history, especially of: severe liver disease, diabetes (poorly controlled), other stomach problems (e.g., tumors)
Contraindications
Panloc (Pantoprazole) enteric coated tablets are contraindicated in patients with known hypersensitivity to any of the formulation.
Drug Interaction
Pantoprazole is metabolized in the liver by the cytochrome P-450 system and subsequently undergoes Phase II conjugation. Studies evaluating possible interactions of pantoprazole with other drugs metabolized by the cytochrome P-450 system found that no dosage adjustment was needed with the concomitant use of the following drugs: antipyrine, caffeine, carbamazepine, cisapride, diazepam, diclofenac, digoxin, ethanol, glyburide, levonorgestrel/ethinyl estradiol (an oral contraceptive), metoprolol, nifedipine, phenytoin, theophylline, or warfarin. There was also no interaction with concomitantly administered antacids.
Storage
Store Panloc at room temperature less than 30°C and keep in cool and dry place, away from moisture and sunlight. Keep the medicine out of the reach of children.